Literature DB >> 8408618

Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.

K Ikewaki1, D J Rader, T Sakamoto, M Nishiwaki, N Wakimoto, J R Schaefer, T Ishikawa, T Fairwell, L A Zech, H Nakamura.   

Abstract

Deficiency of the cholesteryl ester transfer protein (CETP) in humans is characterized by markedly elevated plasma concentrations of HDL cholesterol and apoA-I. To assess the metabolism of HDL apolipoproteins in CETP deficiency, in vivo apolipoprotein kinetic studies were performed using endogenous and exogenous labeling techniques in two unrelated homozygotes with CETP deficiency, one heterozygote, and four control subjects. All study subjects were administered 13C6-labeled phenylalanine by primed constant infusion for up to 16 h. The fractional synthetic rates (FSRs) of apoA-I in two homozygotes with CETP deficiency (0.135, 0.134/d) were found to be significantly lower than those in controls (0.196 +/- 0.041/d, P < 0.01). Delayed apoA-I catabolism was confirmed by an exogenous radiotracer study in one CETP-deficient homozygote, in whom the fractional catabolic rate of 125I-apoA-I was 0.139/d (normal 0.216 +/- 0.018/d). The FSRs of apoA-II were also significantly lower in the homozygous CETP-deficient subjects (0.104, 0.112/d) than in the controls (0.170 +/- 0.023/d, P < 0.01). The production rates of apoA-I and apoA-II were normal in both homozygous CETP-deficient subjects. The turnover of apoA-I and apoA-II was substantially slower in both HDL2 and HDL3 in the CETP-deficient homozygotes than in controls. The kinetics of apoA-I and apoA-II in the CETP-deficient heterozygote were not different from those in controls. These data establish that homozygous CETP deficiency causes markedly delayed catabolism of apoA-I and apoA-II without affecting the production rates of these apolipoproteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408618      PMCID: PMC288323          DOI: 10.1172/JCI116750

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins.

Authors:  H B Brewer; T Fairwell; A LaRue; R Ronan; A Houser; T J Bronzert
Journal:  Biochem Biophys Res Commun       Date:  1978-02-14       Impact factor: 3.575

2.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

3.  Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study.

Authors:  G Heiss; I Tamir; C E Davis; H A Tyroler; B M Rifkand; G Schonfeld; D Jacobs; I D Frantz
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

4.  Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women.

Authors:  E A Brinton; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Demonstration of human apolipoprotien A in isolated mucosal cells from small intestine and isolated hepatocytes.

Authors:  U Hopf; G Assmann; H E Schaefer; A Capurso
Journal:  Gut       Date:  1979-03       Impact factor: 23.059

6.  Comparison of current methods for high-density lipoprotein cholesterol quantitation.

Authors:  G R Warnick; M C Cheung; J J Albers
Journal:  Clin Chem       Date:  1979-04       Impact factor: 8.327

Review 7.  The plasma lecithins:cholesterol acyltransferase reaction.

Authors:  J A Glomset
Journal:  J Lipid Res       Date:  1968-03       Impact factor: 5.922

8.  Multicompartmental analysis of cholesterol metabolism in man. Quantitative kinetic evaluation of precursor sources and turnover of high density lipoprotein cholesterol esters.

Authors:  C C Schwartz; M Berman; Z R Vlahcevic; L Swell
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

9.  Human apolipoprotein A-I and A-II metabolism.

Authors:  E J Schaefer; L A Zech; L L Jenkins; T J Bronzert; E A Rubalcaba; F T Lindgren; R L Aamodt; H B Brewer
Journal:  J Lipid Res       Date:  1982-08       Impact factor: 5.922

10.  Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.

Authors:  E J Schaefer; W H Heaton; M G Wetzel; H B Brewer
Journal:  Arteriosclerosis       Date:  1982 Jan-Feb
View more
  24 in total

Review 1.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 2.  In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease.

Authors:  Katsunori Ikewaki
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

3.  Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility.

Authors:  W Weng; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

Authors:  Margaret E Brousseau; Margaret R Diffenderfer; John S Millar; Chorthip Nartsupha; Bela F Asztalos; Francine K Welty; Megan L Wolfe; Mats Rudling; Ingemar Björkhem; Bo Angelin; James P Mancuso; Andres G Digenio; Daniel J Rader; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-10       Impact factor: 8.311

5.  Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Authors:  Gissette Reyes-Soffer; John S Millar; Colleen Ngai; Patricia Jumes; Ellie Coromilas; Bela Asztalos; Amy O Johnson-Levonas; John A Wagner; Daniel S Donovan; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Tiffany Thomas; Richard L Dunbar; Emil M deGoma; Hashmi Rafeek; Amanda L Baer; Yang Liu; Michael E Lassman; David E Gutstein; Daniel J Rader; Henry N Ginsberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-10       Impact factor: 8.311

Review 6.  Human genetics of variation in high-density lipoprotein cholesterol.

Authors:  Atif Qasim; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

7.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

8.  Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.

Authors:  Mengyang Liu; Yuanli Chen; Ling Zhang; Qixue Wang; Xingzhe Ma; Xiaoju Li; Rong Xiang; Yan Zhu; Shucun Qin; Yang Yu; Xian-cheng Jiang; Yajun Duan; Jihong Han
Journal:  J Biol Chem       Date:  2015-04-25       Impact factor: 5.157

Review 9.  Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein.

Authors:  Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

10.  Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.

Authors:  M E Brousseau; S Santamarina-Fojo; L A Zech; A M Bérard; B L Vaisman; S M Meyn; D Powell; H B Brewer; J M Hoeg
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.